References
- 1. McMurray JJ V, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. Rev Port Cardiol. 2013;32(7-8):e1--641--e61.doi:10.1093/eurheartj/ehs104.10.1093/eurheartj/ehs104
- 2. Ma J, Zhao Y,Wang Y, Guo Y, Li J. Tumor marker levels in patients aged 85 years and older with chronic heart failure. Eur J Intern Med. 2013;24(5):440-443. doi:10.1016/j.ejim.2013.04.002.10.1016/j.ejim.2013.04.002
- 3. Miñana G, Palau P, Núñez J, Sanchis J. The Tumor Marker CA125 and Heart Failure. Eur Heart J. 2010;31(14):1752-1763. doi:10.1093/eurheartj/ehq142.10.1093/eurheartj/ehq142
- 4. Turgut O, Tandogan I, Yilmaz MB, Gul I, Zorlu A. CA125 in heart failure: Implications for immunoinflammatory activity. Int J Cardiol. 2011;146(1):99-100. doi:10.1016/j.ijcard.2010.05.077.10.1016/j.ijcard.2010.05.077
- 5. Huang F, Zhang K, Chen J, et al. Elevation of carbohydrate antigen 125 in chronic heart failure may be caused by mechanical extension of mesothelial cells from serous cavity effusion. Clin Biochem. 2013;46(16-17):1694-1700. doi:10.1016/j.clinbiochem.2013.09.008.10.1016/j.clinbiochem.2013.09.008
- 6. Monteiro S, Franco F, Costa S, et al. Prognostic value of CA125 in advanced heart failure patients. Int J Cardiol. 2010;140(1):115-118. doi:10.1016/j.ijcard.2008.11.023.10.1016/j.ijcard.2008.11.023
- 7. Turgut O, Tandogan I, Yilmaz MB, Gul I, Gurlek A. CA125 levels among patients with advanced heart failure: An emerging independent predictor for survival. Int J Cardiol. 2010;145(1):71. doi:10.1016/j.ijcard.2009.04.030.10.1016/j.ijcard.2009.04.030
- 8. Zorlu A, Tandogan I, Yilmaz MB. CA-125, an omitted part of the heart. Hear Lung Circ. 2011;20(5):345. doi:10.1016/j.hlc.2011.01.025.
- 9. D’Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: Relation to clinical severity, hemodynamic and doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol. 2003;41(10):1805-1811. doi:10.1016/S0735-1097(03)00311-5.
- 10. Núñez J, Miñana G, González M, et al. Antigen carbohydrate 125 in heart failure: Not just a surrogate for serosal effusions? Int J Cardiol. 2011;146(3):473-474. doi:10.1016/j.ijcard.2010.12.027.
- 11. Nunez J, Llacer P, Nunez E, et al. Antigen carbohydrate 125 and creatinine on admission for prediction of renal function response following loop diuretic administration in acute heart failure. Int J Cardiol. 2014;174(3):516-523. doi:10.1016/j.ijcard.2014.04.113.10.1016/j.ijcard.2014.04.113
- 12. Núñez J, Núñez E, Sanchis J, et al. Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure. Int J Cardiol. 2012;159(1):21-28. doi:10.1016/j.ijcard.2011.02.001.10.1016/j.ijcard.2011.02.001
- 13. Vizzardi E, D’Aloia A, Pezzali N, Bugatti S, Curnis A, Dei Cas L. Long-term prognostic value of CA 125 serum levels in mild to moderate heart failure patients. J Card Fail. 2012;18(1):68-73. doi:10.1016/j.cardfail.2011.09.012.10.1016/j.cardfail.2011.09.012
- 14. Miñana G, Palau P, Núñez J, Sanchis J. The Tumor Marker CA125 and Heart Failure. Rev Española Cardiol (English Ed. 2010;63(10):1213-1214. doi: 10.1016/S1885-5857(10)70240-1.
- 15. Yilmaz MB, Nikolaou M, Solal AC. Tumour biomarkers in heart failure: Is there a role for CA-125? Eur J Heart Fail. 2011;13(6):579-583. doi:10.1093/eurjhf/hfr022.10.1093/eurjhf/hfr022
- 16. Topatan B, Basaran A. CA-125 and heart failure: Deja vu or “still to be seen.” Int J Cardiol. 2010;145(3):626-629. doi:10.1016/j.ijcard.2010.09.060.10.1016/j.ijcard.2010.09.060
- 17. Huang F, Chen J, Liu Y, Zhang K, Wang J, Huang H. New mechanism of elevated CA125 in heart failure: The mechanical stress and inflammatory stimuli initiate CA125 synthesis. Med Hypotheses. 2012;79(3):381-383. doi:10.1016/j.mehy.2012.05.042.10.1016/j.mehy.2012.05.042
- 18. Napan S, Aussawapokee T, Nargileci E, Qureshi A, Khadra S, Stroger JH. Prognostic Significance of Carbohydrate Antigen 125 in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2010;55(10):A30.E292. doi:10.1016/S0735-1097(10)60293-8.
- 19. Nunez J, Minana G, Nunez E, Sanchis J. Antigen carbohydrate 125 in heart failure: A promising clinical tool. Int J Cardiol. 2011;150(3):369-370. doi:10.1016/j.ijcard.2011.05.089.10.1016/j.ijcard.2011.05.089
- 20. Sánchez-Marteles M, Rubio Gracia J, Giménez López I. Pathophysiology of acute heart failure: a world to know. Rev Clin Esp. 2015;216(1):38-46. doi:10.1016/j.rce.2015.09.010.10.1016/j.rce.2015.09.010
- 21. Nunez J, Merlos P, Facila L, et al. Prognostic effect of carbohydrate antigen 125-guided therapy in patients recently discharged for acute heart failure (CHANCEHF). Study design. [Spanish]. Rev Esp Cardiol. 2015;68(2):121-128. doi:http://dx.doi.org/10.1016/j.recesp.2014.03.018.10.1016/j.recesp.2014.03.018